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Primary Pulmonary Hypertension Is Associated With
Reduced Pulmonary Vascular Expression of Type II Bone
Morphogenetic Protein Receptor
Carl Atkinson, BSc; Susan Stewart, FRCPath; Paul D. Upton, PhD; Rajiv Machado, PhD;
Jennifer R. Thomson, MRCP; Richard C. Trembath, FRCP; Nicholas W. Morrell, MD
Background—Mutations in the type II receptor for bone morphogenetic protein (BMPR-II), a receptor member of the
transforming growth factor- (TGF-) superfamily, underlie many familial and sporadic cases of primary pulmonary
hypertension (PPH).
Methods and Results—Because the sites of expression of BMPR-II in the normal and hypertensive lung are unknown, we
studied the cellular localization of BMPR-II and the related type I and II receptors for TGF- by immunohistochemistry
in lung sections from patients undergoing heart-lung transplantation for PPH (n11, including 3 familial cases) or
secondary pulmonary hypertension (n6) and from unused donor lungs (n4). In situ hybridization was performed for
BMPR-II mRNA. Patients were screened for the presence of mutations in BMPR2. In normal lungs, BMPR-II
expression was prominent on vascular endothelium, with minimal expression in airway and arterial smooth muscle. In
pulmonary hypertension cases, the intensity of BMPR-II immunostaining varied between lesions but involved
endothelial and myofibroblast components. Image analysis confirmed that expression of BMPR-II was markedly
reduced in the peripheral lung of PPH patients, especially in those harboring heterozygous BMPR2 mutations. A less
marked reduction was also observed in patients with secondary pulmonary hypertension. In contrast, there was no
difference in level of staining for TGF-RII or the endothelial marker CD31.
Conclusions—The cellular localization of BMPR-II is consistent with a role in the formation of pulmonary vascular lesions
in PPH, and reduced BMPR-II expression may contribute to the process of vascular obliteration in severe pulmonary
hypertension. (Circulation. 2002;105:1672-1678.)
Key Words: hypertension, pulmonary  immunohistochemistry  receptors
Primary pulmonary hypertension (PPH) is a rare disorder,with an estimated incidence of 1 to 2 per million per
year.1 The disease is characterized by vascular cell prolifer-
ation and obliteration of small pulmonary arteries,2 which
leads to severe pulmonary hypertension (PH) and right
ventricular failure. Typical morphological appearances in-
clude increased muscularization of small arteries and thick-
ening or fibrosis of the intima.3 The term plexogenic arteri-
opathy is used because of the existence of plexiform lesions
(200 to 400 m in diameter), which are capillary-like
channels adjacent to small pulmonary arteries.4
Recently, heterozygous germline mutations that involve
the gene encoding the type II bone morphogenetic protein
receptor (BMPR2), a member of the transforming growth
factor- (TGF-) receptor superfamily, have been found to
underlie many cases of familial5,6 and sporadic7 PPH. The
precise molecular mechanisms of disease pathogenesis re-
main to be elucidated but are likely to involve altered
BMPR-II function.8 In support of this, we recently found that
compared with cells from control subjects or patients with
secondary PH, pulmonary artery smooth muscle cells from
patients with PPH fail to respond to the growth-suppressive
effects of bone morphogenetic proteins (BMPs).9
Further insight into the role of mutant BMPR-II in the
pathogenesis of PPH would be gained by detailed knowledge
of the cellular distribution of this receptor in the normal and
PH lung. This information might also be useful to identify the
key cell types involved in initiation of the disease. The aim of
the present investigation was to determine the pattern of
expression and cellular localization of BMPR-II in the human
lung. Considerably more is known regarding the expression
of TGF- receptors in the normal and diseased systemic
vasculature, where abnormal TGF- signaling contributes to
the pathogenesis of atherosclerosis10 and restenosis after
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injury.11 It has been suggested that an additional acquired
somatic mutation may be necessary for the clinical manifes-
tation of PPH in a genetically susceptible individual.5 This
hypothesis remains attractive, because somatic mutations in
the TGF- signaling pathway are relatively common and may
contribute to the pathogenesis of certain tumors12 and
atherosclerosis.13
In the present study, we demonstrate that BMPR-II mRNA
and protein expression is mainly localized to the endothelium
in the normal pulmonary circulation, although it is also
expressed by myofibroblasts comprising concentric intimal
lesions in severe PH. In addition, we report that pulmonary
vascular BMPR-II expression is reduced in PPH cases, most
markedly in those PPH cases with an underlying mutation in
the BMPR2 gene.
Methods
Lung Tissue Preparation
The PH lung tissue used in the present study comprised material
from patients undergoing heart-lung transplantation for PPH (n11)
or secondary PH (n6) at Papworth Hospital, Cambridgeshire, UK.
The Huntingdon Local Research Ethics Committee approved this
study. Material was fixed in 10% phosphate-buffered formalin by
airway perfusion immediately after resection, then processed for
sectioning (3 m). Samples were selected from specimens that
showed features of excellent tissue preservation and adequate lung
inflation. Adult control lung was obtained from unused donor lungs
for heart-lung transplantation.
Immunohistochemistry
Paraffin-embedded lung sections were processed by an antigen
retrieval technique. Endogenous peroxidase was quenched by treat-
ment with hydrogen peroxide (Dako). Sections were microwaved
(Euroserv 750-W microwave) on full power for 10 minutes in 0.01
mol/L sodium citrate solution (pH 6). Anti-BMPR-II polyclonal
antibody designated SMN (a gift from Dr K. Miyazono, Tokyo,
Japan14; dilution 1:30) was raised against a peptide corresponding to
amino acid residues 185 to 202 of the 1038–amino acid BMPR-II
sequence. Polyclonal antibodies raised against the human TGF-
type I receptor (TGF-RI; 10 g/mL) and TGF- type II receptor
(TGF-RII; 10 g/mL) were obtained from Research Diagnostics,
Inc. To identify cells of endothelial lineage in serial sections, the
monoclonal antiendothelial cell markers (all from Dako) anti-CD31
(1:80), anti-von Willebrand factor (1:20), anti-CD34 (1:400) were
used. The monoclonal anti--smooth muscle actin (Dako) identified
cells of smooth muscle lineage, and anti-CD68 (1:400) (Dako)
identified macrophage cells. Primary antibodies were incubated for 1
hour at room temperature. Antigen was visualized with a labeled
streptavidin biotin peroxidase technique (Dako Chemate LSAB,
Dako) with diaminobenzine substrate. Control and PH cases were
batched (25 to 50 sections) and processed together in a semiauto-
mated protocol (Dako Techmate 500 autostainer). The specificity of
immunostaining was demonstrated by the absence of signal in
sections incubated with antibody after absorption with the peptide
against which the antibody was raised and after omission of the
primary antibody. Sections were then counterstained with hematox-
ylin and examined by light microscopy.
Image Analysis
Two methods were used to semiquantify the results of immunohis-
tochemistry. First, PH sections were examined by 2 observers
unaware of the underlying diagnosis (C.A. and N.W.M.). The
observers identified lesions and classified them as concentric intimal
lesions or plexiform lesions. Immunostaining for BMPR-II, TGF-
RII, and CD31 was classified as present or absent and the number
of positive lesions expressed as a percentage of the total number of
lesions in each case. Second, images were acquired from 5 randomly
selected fields and stored as digital image files. Images were
imported into an image-analysis software package (Aeqatis). This
allowed calculation of the total tissue area and the area of positive
immunostaining, which was then expressed as a percentage.
In Situ Hybridization
A 424-bp cDNA fragment (nucleotides 803 to 1226) of human
BMPR-II cDNA was ligated into the PstI/XhoI site of the plasmid
Clinical Data for Patients With PH
Patient Sex/Age, y
Mean PAP,
mm Hg
Cardiac Output,
L/min
Underlying
Condition
Final
Diagnosis
BMPR2 Mutation
Analysis
1 M/41 79 3.2 None PPH ND
2 F/25 95 3.1 None PPH Partial deletion
3 M/48 56 NA None FPPH Partial deletion
4 M/23 88 3.5 None PPH ND
5 F/50 90 3.0 None PPH ND
6 F/19 69 2.7 None PPH ND
7 F/28 70 3.5 None FPPH 2q33 Allele sharing
8 F/59 67 2.6 None FPPH 355delA
9 F/36 73 3.7 None PPH ND
10 M/46 NA NA None PPH ND
11 F/41 60 NA None PPH ND
12 F/42 NA NA VSD SPH ND
13 F/47 NA NA VSD SPH ND
14 F/30 NA NA VSD SPH ND
15 F/31 82 NA VSD SPH ND
16 M/35 97 2.6 CTE SPH ND
17 F/33 54 NA Scleroderma SPH ND
PAP indicates pulmonary arterial pressure; NA, not available; FPPH, familial PPH; ND, not detected; VSD, ventricular
septal defect; SPH, secondary PH; and CTE, chronic thromboembolism.
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vector pBluescriptKS(). In vitro transcription from the T3 and T7
promoters yielded antisense and sense probes, respectively. Tran-
scripts were labeled with sulfur-35-uridine triphosphate (35S-UTP;
1200 Ci · mmol1 · L1; New England Nuclear). After hybridiza-
tion with cRNA probe, slides were processed as described previous-
ly.15 Slides were exposed for up to 10 weeks at 4°C. After
development of the photographic emulsion, slides were stained with
hematoxylin and eosin. Silver grains were visualized by light- and
dark-field microscopy.
Mutation Analysis of the BMPR2 Gene
The entire protein-coding region and intron/exon boundaries of the
BMPR2 gene were amplified by polymerase chain reaction, as
described previously.5 Amplified fragments were sequenced with a
dye-terminator cycle-sequencing system (ABI PRISM 377, Perkin-
Elmer Applied Biosystems). In addition, gene dosage analysis of
BMPR2 exons 1 and 12 was performed to detect partial gene
deletions, as described previously.8 In 1 individual with familial PPH
in whom no BMPR2 mutations were identified by these methods,
allele-sharing studies of the BMPR2 locus were performed, as
described previously.16
Results
Clinical Data
Clinical data for patients with PPH and secondary PH are
shown in the Table.
Mutation Analysis of the BMPR2 Gene
A total of 3 germline BMPR2 mutations were detected among
the 11 PPH patients studied. Direct DNA sequencing was
used to identify an exon 3 frameshift mutation (355delA) in
1 patient with familial PPH (patient 8) that created a prema-
ture truncating codon, which, if translated, may fail to reach
the cell surface.5 BMPR2 gene dosage studies determined
heterozygous partial gene deletions in 1 patient with familial
PPH (patient 3) and 1 with sporadic PPH (patient 2), the
extent of which remains to be determined.8 In the remaining
patient with familial PPH (patient 7), no BMPR2 mutations
were detected; however, allele-sharing studies in this family
were consistent with linkage to the BMPR2 locus at 2q33. No
mutations in BMPR2 were identified in patients with second-
ary PH.
Cell Types Comprising Vascular Lesions
We performed immunohistochemical studies to determine the
main cell types present within vascular lesions in PH.
Expression of endothelial cell markers was confined to the
monolayer of cells lining vascular channels (Figure 1). The
remaining cell layers comprising concentric lesions stained
heavily for -smooth muscle actin (Figure 1). Although the
vascular channels of plexiform lesions stained for endothelial
cell markers, the stroma surrounding these channels also
stained for -smooth muscle actin. Staining with anti-CD68
demonstrated the presence of macrophages in many lesions
(Figure 1).
Expression of BMPR-II mRNA and Protein
In normal lungs, hybridization to BMPR-II mRNA was
predominantly observed on vascular endothelial cells, with
focal expression in the underlying smooth muscle and inter-
stitial cells, which appeared to be macrophages (Figure 2).
The signal was similar in endothelial cells that lined larger
(200- to 500-m diameter) and small (200 m-diameter)
pulmonary arteries and alveolar capillary endothelium. De-
spite repeated attempts, specific hybridization to BMPR-II
mRNA was low in PH cases (not shown). Immunohistochem-
istry confirmed the predominantly endothelial localization of
BMPR-II protein in normal lung (Figure 3) but also suggested
some focal weaker expression by vascular smooth muscle.
BMPR-II immunostaining was also demonstrated in macro-
phages. In PH cases, BMPR-II protein expression was ob-
served on endothelial cells and myofibroblasts comprising
intimal lesions (Figure 3). Endothelial cells lining the vascu-
lar channels of plexiform lesions also expressed BMPR-II
(Figure 3).
Immunolocalization of TGF- Receptors
In normal lungs, TGF-RI and TGF-RII colocalized pre-
dominantly to vascular endothelium, with focal staining of
the underlying smooth muscle (Figure 4). However, airway
epithelial staining was also prominent. In PPH and secondary
PH, TGF-RI and TGF-RII immunostaining remained
prominent on endothelial cells, including those of plexiform
lesions, as well as on myofibroblast cells comprising intimal
lesions.
Figure 1. Photomicrographs of lung sections from patients with
PPH demonstrating cellular composition of vascular lesions.
Plexiform lesions demonstrate positive immunostaining of endo-
thelial marker CD31 (A) on single layer of cells lining endothelial
channels (arrowed), whereas supporting stroma of plexiform
lesion stains positively for -smooth muscle actin (B). In con-
centric intimal lesions, single layer of cells adjacent to vascular
lumen (arrow) stains for endothelial markers CD31 (C) or von
Willebrand factor (E). Concentric layers of cells comprising vas-
cular wall stain for -smooth muscle actin (D). Numerous mac-
rophages stained with anti-CD68 are present within many
lesions (arrowed; F). Approximate magnification 200.
1674 Circulation April 9, 2002
 by guest on September 29, 2012http://circ.ahajournals.org/Downloaded from 
Semiquantification of Immunostaining
Comparison of the staining intensity of endothelial cells for
BMPR-II revealed a generally reduced level of BMPR-II
protein expression in PPH cases compared with control or
secondary PH cases (Figure 5). Semiquantification of the
level of immunostaining by image analysis revealed that
staining was significantly decreased in all PH cases, with the
most marked reductions observed in PPH cases that harbored
mutations predicted to cause loss of protein expression or
linkage to the BMPR2 locus (Figure 6). In contrast, the area
of tissue stained by anti-CD31 and anti-TGF-RII was
similar between groups (Figure 6).
Because some vascular lesions in PH cases appeared not to
stain for BMPR-II, we performed a further analysis to
compare the proportion of vascular lesions that were positive
for BMPR-II and TGF-RII in each PH group. Between 5
and 12 lesions were examined per case. The proportion of
positive stained lesions was reduced in PPH cases that
harbored a mutation or demonstrated linkage to 2q33 (Figure
7). In contrast, similar proportions of lesions stained posi-
tively for TGF-RII between groups (Figure 7).
Discussion
This study has demonstrated the cellular distribution of
BMPR-II in the normal and hypertensive lung. Our observa-
Figure 2. Light-field (A and B) and dark-field (C and D) photomi-
crographs of in situ hybridization for BMPR-II mRNA expression
in normal pulmonary artery. Antisense probe (A and C) demon-
strated BMPR-II mRNA expression predominantly in endothelial
cells lining vascular lumen, with focal expression by underlying
medial smooth muscle cells. Incubation of sections with control
(sense) probe (B and D) showed no hybridization. Approximate
magnification 200.
Figure 3. Photomicrographs of lung immunostained for BMPR-
II. In normal arteries (A and B), BMPR-II immunostaining pre-
dominates in endothelium (arrowed). In vascular lesions of PPH
(C through F) and secondary PH (D and E), endothelial staining
is again prominent, including cells lining vascular channels of
plexiform lesions (C, arrowed) and endothelial cells lining con-
centric lesions (D through F). In addition, BMPR-II expression is
noted on myofibroblast cells comprising intimal lesions (D).
Approximate magnification 200.
Figure 4. Photomicrographs of lung immunostained with anti-
TGF-RI (A and B) or anti-TGF-RII (C through F). A, TGF-RI
immunostaining is prominent on endothelial cells lining normal
pulmonary artery, with focal staining of underlying smooth mus-
cle. B, Within intimal lesions, TGF-RI is found on endothelium
and on underlying myofibroblasts within lesion. TGF-RII has
similar distribution in normal artery (C) and is also prominent on
airway epithelial cells (D). In concentric intimal lesions, endothe-
lial and underlying myofibroblast expression of TGF-RII is
observed (E and F). The majority of plexiform lesions also
expressed abundant TGF-RII (F, arrowed). Approximate magni-
fication 100 (D), 200 (A,C,E,F), and 400 (B).
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tions suggest that this receptor is predominantly expressed by
endothelial cells in the pulmonary circulation, with a lower
level of expression in vascular smooth muscle. In addition,
BMPR-II is expressed within the characteristic lesions found
in PPH, specifically by endothelial cells of plexiform lesions
and by endothelial and myofibroblast cells in the intimal
lesions. The cellular localization of BMPR-II to key cell types
implicated in the vascular remodeling of PPH supports
the suggestion from genetic studies that mutations in this
receptor play a causal role in disease pathogenesis. Further-
more, the observation that BMPR-II protein expression is
reduced in the lungs of patients with severe PH, most
markedly in patients harboring heterozygous germline muta-
tions in BMPR2, suggests that reduced BMPR-II signaling
may be implicated not only in the in the pathogenesis of PPH
in which BMPR2 mutations have been identified but also in
other mutation-negative cases of PPH, and possibly in sec-
ondary forms of PH.
To the best of our knowledge, this is the first study to
examine the cellular localization of BMPR-II expression in
human lung. Northern blots have revealed that BMPR-II is
widely expressed in various human tissues, with a high level
of expression in lung tissue.14 Although BMPR-II mRNA was
readily demonstrated in normal lungs, we could not reliably
detect hybridization in diseased lungs. In light of our immu-
nohistochemical findings, it may be that reduced expression
of BMPR-II protein in severe PH is, at least in part,
transcriptionally regulated.
We performed mutation analysis of genomic DNA from all
patients with severe PH. Three germline mutations were
identified (1 frameshift and 2 partial deletions) that were
predicted to cause reduced expression of BMPR-II protein.8
In another familial PPH case, no mutation was identified, but
linkage to the BMPR2 locus at 2q33 was demonstrated.
Comparison of the level of immunostaining in known mu-
tants with that in other PPH and secondary PH cases revealed
an obvious reduction in the level of BMPR-II protein expres-
sion, with absent expression in some lesions. The complete
lack of staining within some vascular lesions was most
evident in the PPH cases with BMPR2 mutation or evidence
of linkage. Further semiquantification of the area of periph-
eral lung tissue stained positively for BMPR-II revealed that
BMPR-II protein expression was dramatically reduced in
PPH cases with BMPR2 mutation or linkage. However, there
was also a marked reduction in the level of BMPR-II
immunostaining in PPH cases in which no mutation was
identified. In these cases, the endothelium remained intact, as
judged by a normal level of staining for CD31. Moreover, the
observation appeared specific for BMPR-II in that the level of
immunostaining for a related receptor, TGF-RII, was simi-
lar between groups. Interestingly, a less marked but signifi-
cant reduction in the level of BMPR-II immunostaining was
also observed in secondary PH. These results suggest that
reduced expression of BMPR-II may contribute not only to
the pathogenesis of PPH but also to other forms of severe PH.
Similar reductions in the level of expressed protein have been
Figure 5. Photomicrographs of peripheral lung stained for
BMPR-II from control subject (A) and patients with secondary
PH (patient 12; B), PPH in which no BMPR2 mutation was iden-
tified (patient 4; C), and PPH in which truncating mutation in
BMPR2 was identified (patient 8; D). Note reduced alveolar cap-
illary staining for BMPR-II (arrowed) compared with control, par-
ticularly in PPH cases. Approximate magnification 200.
Figure 6. Semiquantification of lung tissue area positively
stained for BMPR-II (A), TGF-RII (B), and CD31 (C) in controls
and patient groups. SPH indicates secondary PH. *P0.05 vs
control, #P0.05 vs SPH, P0.05 vs PPH, by ANOVA and
Tukey multiple comparison test.
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noted in hereditary hemorrhagic telangiectasia, with an un-
derlying heterozygous null mutation in the gene encoding
endoglin.17 An intriguing possibility is that additional loss of
the wild-type BMPR2 allele or reduction in BMPR2 tran-
scription may be necessary to trigger the formation of
vascular lesions in patients harboring a germline mutation.
This “second hit” might explain the low penetrance of the
condition within families.5 Additional molecular analysis of
individual lesions will be necessary to determine whether
such a mechanism occurs. Analysis of tissue from the
systemic circulation of PPH patients would be necessary to
determine whether the marked reduction in BMPR-II expres-
sion is restricted to the lung, which may in part explain the
lung-specific nature of this disease.
A recent report identified an increased frequency of so-
matic mutations that arose as a result of microsatellite
instability in the TGF-RII gene18 in plexiform lesions of
PPH patients. The present study found that20% of vascular
lesions in severe PH demonstrated absent expression of
TGF-RII but no difference in the frequency of negative
lesions between PPH and secondary PH groups. However, it
remains conceivable that germline mutations in BMPR2 and
somatic mutation in TGF-RII may have similar and/or
additive effects, removing the growth-inhibitory effect of
TGF- superfamily members and allowing clonal expansion
of vascular cells, leading to occlusion of small pulmonary
arteries.
Although a limited number of studies have suggested a role
for TGF- in hypertensive pulmonary vascular remodeling,19
its precise role is poorly defined. Immunostaining for TGF-
isoforms, especially TGF-2 and TGF-3, appears to be
increased in actively remodeling hypertensive pulmonary
arteries in patients with PPH compared with controls.19
However, TGF- is not a known ligand for BMPR-II, and the
cellular localization of BMP expression in the lung is yet to
be determined.
We have recently reported that pulmonary artery smooth
muscle cells from patients with PPH exhibit altered growth
responses to BMPs in that BMPs suppress proliferation of
cells from normal controls and secondary PH patients but not
PPH patients.9 We speculate that the failure of BMP-induced
growth suppression may contribute to abnormal proliferation
of vascular cells in PPH. Interestingly, in that study,9 cells
from all PPH patients behaved similarly, whether a mutation
in BMPR2 was present or not. The findings of the present
study provide a possible explanation for this in that markedly
reduced BMPR-II expression was a feature of all PPH cases,
whether or not BMPR2 mutations were present. Thus, re-
duced expression of BMPR-II protein, either as a result of
underlying mutation or transcriptional repression of BMPR2,
may contribute to the abnormal vascular cell responses to
BMPs in PPH.
The nature of the cell type responsible for the intimal
obliteration of small pulmonary arteries in PPH has been the
subject of considerable debate.3,18,20 The evidence, supported
by our findings, suggests that the intimal lesion is composed
of myofibroblast-like cells, which stain positively for
-smooth muscle actin and vimentin, and that the expression
of endothelium-specific markers is confined to cells lining the
vascular lumen.3,21 The plexiform lesion would appear to
consist of a proliferation of endothelial cells supported by a
myofibroblast stroma.3,4,22,23
In summary, the present study identifies predominantly
endothelial cells but also myofibroblast cells comprising
intimal lesions as the sites of pulmonary vascular expression
of BMPR-II in PPH and secondary PH. The reduced or absent
expression of BMPR-II in vascular lesions of PPH patients,
especially in those harboring an underlying mutation in the
BMPR2 gene, supports the hypothesis that loss of BMPR-II
function contributes to the formation of lesions.
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